The Cancer Stem Cell Therapies Market, 2017-2030' report examines the current landscape and the future outlook of the growing pipeline of products targeting CSCs. We identified over 150 molecules that are currently being investigated as therapeutic interventions for the elimination of CSCs. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry.
The objective of the ongoing R&D is to develop novel CSC directed treatments that can combat complications, such as off target toxicities and disease relapse, associated with the current standard of care treatments. In fact, between January 2008 and December 2016, the number of publications in this domain grew at an annualized rate of 10.4%; overall, there are over 9000 publications available on PubMed, indicating the extensive research activity unfolding in this domain.
One of the key objectives of the report was to estimate the future size of the CSC therapy market, specifically in the US and EU. We adopted a bottom-up approach to evaluate the likely success and growth of marketed drugs and those that are in phase II and phase III of clinical development, over the next 10-15 years.
The insights generated on the future opportunity are segmented on the basis of key indications, important target strategies and key products. In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the period 2017-2030, namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry's evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research.
The report presents details of conversations with (in alphabetical order of company name) Stephen Franklin (CEO, Evgen Pharma), Steven Swanson (Senior Vice President, ImmunoCellular Therapeutics) and Jaffer Ajani (Researcher at MD Anderson Cancer Center).
Key Topics Covered:
2. Executive Summary
4. Competitive Landscape
5. Key Insights
6. Emerging Trends On Social Media
7. Publication Analysis
8. Marketed And Late-Stage Drugs: Detailed Profiles
9. Phase II Molecules: Tabulated Profiles
10. Market Forecast And Opportunity Analysis
12. Interview Transcripts
13. Appendix 1: Tabulated Data
14. Appendix 2: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/research/8zzgkm/global_cancer?w=4